223

PYGL Antibody | 22-426

(No reviews yet) Write a Review
SKU:
223-22-426-GEN
NULL541.00
Frequently bought together:

Description

PYGL Antibody | 22-426 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-280 of human PYGL (NP_002854.3) .

Research Area: Cancer, Signal Transduction

Tested Application: WB, IF

Application: WB: 1:500 - 1:2000
IF: 1:50 - 1:200

Specificiy: N/A

Positive Control 1: HL-60

Positive Control 2: SKOV3

Positive Control 3: HepG2

Positive Control 4: Mouse liver

Positive Control 5: Mouse lung

Positive Control 6: Rat liver

Molecular Weight: Observed: 110kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: PYGL, GPLL, Phosphorylase, glycogen liver, Phosphorylase, glycogen, liver, GSD6

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This gene encodes a homodimeric protein that catalyses the cleavage of alpha-1, 4-glucosidic bonds to release glucose-1-phosphate from liver glycogen stores. This protein switches from inactive phosphorylase B to active phosphorylase A by phosphorylation of serine residue 15. Activity of this enzyme is further regulated by multiple allosteric effectors and hormonal controls. Humans have three glycogen phosphorylase genes that encode distinct isozymes that are primarily expressed in liver, brain and muscle, respectively. The liver isozyme serves the glycemic demands of the body in general while the brain and muscle isozymes supply just those tissues. In glycogen storage disease type VI, also known as Hers disease, mutations in liver glycogen phosphorylase inhibit the conversion of glycogen to glucose and results in moderate hypoglycemia, mild ketosis, growth retardation and hepatomegaly. Alternative splicing results in multiple transcript variants encoding different isoforms.

View AllClose

Additional Information

Size:
50 uL
View AllClose